MedTrace Logo

Safety and Tolerability of Seroguard Use

NCT03640559 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-05-03

Study results available
· View outcomes & findings →

Summary

The performed study of safety and tolerability of Seroguard, solution (JSC Pharmasyntez, Russia) in patients, undergoing planned laparoscopic cholecystectomy, demonstrated that patients from the both groups had the similar safety profile

Conditions

  • Adhesion

Interventions

DRUG

Seroguard

DRUG

Placebos

Sponsors & Collaborators

  • Sciencefiles

    collaborator UNKNOWN

  • Pharmasyntez

    lead INDUSTRY

Principal Investigators

  • Mikhail Shurygin, PhD · Pharmasyntez

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-19
Primary Completion
2015-10-04
Completion
2015-10-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03640559 on ClinicalTrials.gov